Long Daniel D. 4

What Happened
Daniel D. Long, Senior Vice President, Drug Discovery at Septerna, was granted a derivative award covering 80,000 shares on February 6, 2026. The Form 4 reports the acquisition as a derivative at $0.00 per share (i.e., an option award rather than an open‑market purchase or sale). No exercise or sale occurred in this filing.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-10 (timely filing).
• Security: derivative (option award) for 80,000 shares reported at $0.00 per share.
• Vesting (footnote): 2/48 of the option shares vest on March 1, 2026; the remaining shares vest in 46 substantially equal monthly installments thereafter, subject to continued service.
• Shares owned after transaction: not specified in the filing.
• Exhibit noted: 24.2 (Substitute Power of Attorney).
• Transaction type: Award/Grant (code A on Form 4); not an exercise or sale.

Context
This entry reflects an equity incentive grant (typical for executive/employee retention and compensation). As a derivative award, it does not represent an immediate purchase or sale of common stock; value is realized only as options vest and are exercised (if exercised). The filing appears timely under Section 16 reporting rules.